Sector · Life Sciences
The FDA and the European Medicines Agency published joint AI Guiding Principles in January 2026. Your next submission will be reviewed against them.
For the Head of Regulatory Affairs who needs an AI governance architecture that satisfies both the FDA’s risk-based framework and the EMA’s lifecycle management requirements simultaneously, not sequentially.
Agentecture for the research, regulatory and manufacturing chain behind every new treatment.
Governing body context
US FDA and European Medicines Agency, joint Guiding Principles of Good AI Practice in Drug Development — published January 2026, covering ten principles across the full product lifecycle. Over 1,000 AI-based medical devices have already been authorised by the FDA since 2016.
Where agentecture tackles the challenge
The structural failures every life sciences operation knows.
01
Drug-discovery timelines remain long and capital intensive, with vast unstructured research data sitting underused across disconnected systems.
02
Regulatory documentation and compliance reporting consume scientific time that should be directed toward research itself.
03
Manufacturing and supply-chain operations carry compliance and traceability requirements stricter than almost any other sector.
04
Procurement and requisition review processes remain slow and manual despite governing access to time-critical research materials.
The evidence — UK & global
Every number traced to the body that governs the sector.
48.4%
of UK life sciences respondents now use AI in some part of their operations, per December 2025 ONS data cited in the UK government’s life sciences AI plan.
500+
submissions containing AI components reviewed by the US FDA since 2016, with first dedicated draft guidance in Jan 2025 and joint FDA–EMA principles in Jan 2026.
1,000+
AI-based medical devices authorised by the FDA as of December 2024, reflecting an exponential increase that prompted its risk-based framework.
10 principles
make up the joint FDA and EMA Guiding Principles of Good AI Practice in Drug Development, published January 2026, covering the full product lifecycle.
How the meaiow ecosystem helps
Six products. One configured workforce.
Manages researcher and partner-facing query resolution and internal knowledge retrieval, reducing time scientists spend searching rather than researching.
Builds the agent workforce for requisition review, regulatory documentation drafting and manufacturing compliance checks, each bounded to a defined scientific or regulatory domain.
Maps the real research, regulatory and manufacturing workflow, identifying where unstructured data and manual review are slowing time to discovery.
Applies the traceability and validation standard set out in the FDA and EMA’s joint Guiding Principles, with every agent-assisted decision auditable against a recognised global framework.
Structures the workforce transition as agents absorb documentation and review work, redirecting scientific time toward genuine discovery.
Trains research, regulatory and manufacturing teams to work alongside a governed agent workforce within a heavily regulated environment.
Speak to a MEAIOW specialist in life sciences AI.
Thirty minutes, sector-specific. We will already know your operating model and the governing-body context before the call.
No obligation. No sales process. Just a clear picture of what is possible.